Honest Opinions

[anonymous]

I know this may be a tough ask for cafepharma but let’s have some honest opinions. It’s obvious that BF having trouble truly becoming an “expert” in PDT. I’m curious what they could do in the next 2-6 months to correct their trajectory. What are the quickest fixes that could lead to some successes they can build off of.

 

[anonymous]

I know this may be a tough ask for cafepharma but let’s have some honest opinions. It’s obvious that BF having trouble truly becoming an “expert” in PDT. I’m curious what they could do in the next 2-6 months to correct their trajectory. What are the quickest fixes that could lead to some successes they can build off of.

Honestly, the only way this company is going to survive is by making changes in upper management. In the last year it's been a race to the bottom with RA and MB in charge. This is nothing personal against them but neither one is equipped to handle the roles which they were given. The therapy is great, the people running the show are not.

 

[anonymous]

Sales YOY without anything new have grown 20%+ so not sure that it’s a sales leadership - MB and RA issue. This is bigger than sales. New indications, 3 tubes, new lamp should finally help this year and next but company also has to cut back on spending, renegotiate contracts w AG, somehow stop Sun from continuing to sue them as this costs them tons of money every year and find investors who are in it for the long haul and don’t just want to make a quick buck. Also who is presenting to the investors and what is the response? Every time the company tries to raise capital, stock drops because current investors likely hear this and drop out. Biofrontera has providers who have grown exponentially with ameluz and red light over the last few years. Why don’t investors speak with them? The company needs 1 or 2 big investors. Also why does levulans wac price never change with all the deep discounts they give? Something is going on there. How does levulans margins remain so big and ameluz so small? This will always prevent top levulan customers from switching to ameluz. Someone needs to investigate this.

 

[anonymous]

Sales YOY without anything new have grown 20%+ so not sure that it’s a sales leadership - MB and RA issue. This is bigger than sales. New indications, 3 tubes, new lamp should finally help this year and next but company also has to cut back on spending, renegotiate contracts w AG, somehow stop Sun from continuing to sue them as this costs them tons of money every year and find investors who are in it for the long haul and don’t just want to make a quick buck. Also who is presenting to the investors and what is the response? Every time the company tries to raise capital, stock drops because current investors likely hear this and drop out. Biofrontera has providers who have grown exponentially with ameluz and red light over the last few years. Why don’t investors speak with them? The company needs 1 or 2 big investors. Also why does levulans wac price never change with all the deep discounts they give? Something is going on there. How does levulans margins remain so big and ameluz so small? This will always prevent top levulan customers from switching to ameluz. Someone needs to investigate this.

Everything you said here is perfectly on the nose. Spoken like someone who should be on the inside. Any chance you need a job. BF should consider bringing you in (or back).

 

[anonymous]

1